drugset / Trial / NCT06679270
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
NaSingle-groupOpen-labelTreatment
Summary
This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
Timeline
- Start
- 2024-10-14
- Primary completion
- 2028-03
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metreleptin | Protein / enzyme biologic | — | Subcutaneous |